{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T05:32:17Z","timestamp":1792733537600,"version":"4.5.0"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T00:00:00Z","timestamp":1718150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>We conducted an overview to assess immune adverse effects associated with the COVID-19 vaccine, guiding safer choices and providing evidence-based information to clinicians.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Forty-three studies on adverse effects of vaccines were reviewed from PubMed, Embase, and Web of Science. Single-arm meta-analyses estimated summary effects, incidence, presentation, etc. An overview using single-arm meta-analysis and reported the findings following the guidelines outlined in the \u2018Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) specifically focusing on myocarditis and thrombosis. After screening 2,591 articles, 42 studies met the inclusion criteria. Methodological quality was evaluated using AMSTAR 2. Disagreements were resolved via consensus. Data analysis utilized a random-effects model in R software to estimate incidence rates of selected adverse events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>After removing 1,198 duplicates and screening out irrelevant articles from a total of 2,591, we included 42 studies. Adverse reactions to vaccinations include myocarditis, thrombosis, skin reactions, GBS, etc. thrombosis and myocarditis are the most dangerous diseases associated with vaccination. Myocarditis occurred in 6% of Vector vaccine recipients, compared to 61% of mRNA vaccine recipients. Thrombosis was more common after Vector vaccination (91%) than after mRNA vaccination (9%). Furthermore, eight studies conducted anti-PF4 antibody tests and yielded a positivity rate of 67%. Meta-analysis showed that among all patients with Vaccine-induced Thrombotic Thrombocytopenia, cerebral venous sinus thrombosis occurred in 66%, and intracranial hemorrhage occurred in 43%. The rates of deep vein thrombosis and pulmonary thromboembolism in vaccinated patients were 13% and 23%, respectively, with a pooled case fatality rate of 30%.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The results of this overview indicate the majority of adverse reactions are self-limiting and require minimal intervention, while rare occurrences such as myocarditis and thrombosis pose a potentially fatal threat.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2024.1308768","type":"journal-article","created":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T07:56:30Z","timestamp":1718178990000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["An overview and single-arm meta-analysis of immune-mediated adverse events following COVID-19 vaccination"],"prefix":"10.3389","volume":"15","author":[{"given":"Donghua","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhui","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caiyi","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,6,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.amjcard.2021.07.006","article-title":"MitraClip in patients with and without cardiac resynchronization therapy","volume":"157","author":"Bansal","year":"2021","journal-title":"Am. J. Cardiol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1056\/NEJMoa2110475","article-title":"Safety of the BNT162b2 mRNA covid-19 vaccine in a nationwide setting","volume":"385","author":"Barda","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41541-022-00569-8","article-title":"Understanding thrombosis with thrombocytopenia syndrome after COVID-19 vaccination","volume":"7","author":"Buoninfante","year":"2022","journal-title":"NPJ Vaccines"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2794","DOI":"10.1016\/j.ymthe.2021.08.001","article-title":"A comprehensive analysis of the efficacy and safety of COVID-19 vaccines","volume":"29","author":"Cai","year":"2021","journal-title":"Mol. Ther."},{"key":"B5","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1080\/14760584.2023.2150169","article-title":"Cardiovascular safety of COVID-19 vaccines in real-world studies: a systematic review and meta-analysis","volume":"22","author":"Chang","year":"2023","journal-title":"Expert Rev. Vaccines"},{"key":"B6","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.patol.2022.09.003","article-title":"A postmortem study of patients vaccinated for SARS-CoV-2 in Colombia","volume":"56","author":"Chaves","year":"2023","journal-title":"Rev. Esp. Patol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.ijcard.2022.01.037","article-title":"Myocarditis after RNA-based vaccines for coronavirus","volume":"353","author":"Cordero","year":"2022","journal-title":"Int. J. Cardiol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1001\/jamacardio.2021.3471","article-title":"Association of myocarditis with BNT162b2 messenger RNA COVID-19 vaccine in a case series of children","volume":"6","author":"Dionne","year":"2021","journal-title":"JAMA Cardiol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s43162-022-00129-5","article-title":"Immune-mediated adverse events post-COVID vaccination and types of vaccines: a systematic review and meta-analysis","volume":"34","author":"ElSawi","year":"2022","journal-title":"Egypt J. Intern Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.amjcard.2021.10.022","article-title":"Incidence of myopericarditis and myocardial injury in coronavirus disease 2019 vaccinated subjects","volume":"164","author":"Farahmand","year":"2022","journal-title":"Am. J. Cardiol2022"},{"key":"B11","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1097\/HM9.0000000000000036","article-title":"etc. Post COVID-19 burden: focus on the short-term condition","volume":"2","author":"Fengwen","year":"2022","journal-title":"Acupunct. Herb. Medicine2022"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1056\/NEJMoa2104840","article-title":"Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination","volume":"384","author":"Greinacher","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"B14","doi-asserted-by":"publisher","first-page":"4662","DOI":"10.1182\/bloodadvances.2021005388","article-title":"VITT following Ad26.COV2.S vaccination presenting without radiographically demonstrable thrombosis","volume":"5","author":"Kennedy","year":"2021","journal-title":"Blood Adv."},{"key":"B15","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.ijid.2022.03.034","article-title":"Thrombosis patterns and clinical outcome of COVID-19 vaccine-induced immune thrombotic thrombocytopenia: a Systematic Review and Meta-Analysis","volume":"119","author":"Kim","year":"","journal-title":"Int. J. Infect. Dis."},{"key":"B16","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.ijid.2022.08.025","article-title":"Corrigendum to 'thrombosis patterns and clinical outcome of COVID-19 vaccine-induced immune thrombotic thrombocytopenia: a systematic review and meta-analysis' international journal of infectious diseases, volume 119, june 2022, page 130-139","volume":"123","author":"Kim","year":"","journal-title":"Int. J. Infect. Dis."},{"key":"B17","doi-asserted-by":"publisher","first-page":"120327","DOI":"10.1016\/j.jns.2022.120327","article-title":"Acute ischemic stroke and vaccine-induced immune thrombotic thrombocytopenia post COVID-19 vaccination; a systematic review","volume":"439","author":"Kolahchi","year":"2022","journal-title":"J. Neurol. Sci."},{"key":"B18","doi-asserted-by":"publisher","first-page":"108906","DOI":"10.1016\/j.intimp.2022.108906","article-title":"Adverse events following COVID-19 vaccination: a systematic review and meta-analysis","volume":"109","author":"Kouhpayeh","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1002\/jmv.27568","article-title":"The effectiveness of mRNA-1273 vaccine against COVID-19 caused by Delta variant: a systematic review and meta-analysis","volume":"94","author":"Kow","year":"2022","journal-title":"J. Med. Virol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"820","DOI":"10.7326\/0003-4819-127-9-199711010-00008","article-title":"Quantitative synthesis in systematic reviews","volume":"127","author":"Lau","year":"1997","journal-title":"Ann. Intern Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e25","DOI":"10.1097\/INF.0000000000003389","article-title":"Population-based incidence of myopericarditis after COVID-19 vaccination in Danish adolescents","volume":"41","author":"Nygaard","year":"2022","journal-title":"Pediatr. Infect. Dis. J."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1344184","DOI":"10.3389\/fimmu.2024.1344184","article-title":"etc. Central nervous system immune-related disorders after SARS-CoV-2 vaccination: a multicenter study","volume":"15","author":"ogrig","year":"2024","journal-title":"Front. Immunol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1001\/jama.2021.24110","article-title":"Myocarditis cases reported after mRNA-based COVID-19 vaccination in the US from december 2020 to august 2021","volume":"327","author":"Oster","year":"2022","journal-title":"JAMA"},{"key":"B24","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1038\/s41591-021-01630-0","article-title":"Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection","volume":"28","author":"Patone","year":"2022","journal-title":"Nat. Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"955","DOI":"10.3390\/diagnostics11060955","article-title":"COVID-19 vaccine and death: causality algorithm according to the WHO eligibility diagnosis","volume":"11","author":"Pomara","year":"2021","journal-title":"Diagn. (Basel)"},{"key":"B26","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1111\/jebm.12510","article-title":"Caution regarding immune-mediated encephalitis post-COVID-19 vaccination","volume":"15","author":"Pothiawala","year":"2022","journal-title":"J. Evid. Based Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e15391","DOI":"10.1111\/dth.15391","article-title":"Cutaneous adverse reactions of COVID-19 vaccines: a systematic review","volume":"35","author":"Qaderi","year":"2022","journal-title":"Dermatol Ther."},{"key":"B28","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/S1473-3099(22)00054-8","article-title":"Safety of mRNA vaccines administered during the initial 6 months of the US COVID-19 vaccination programme: an observational study of reports to the Vaccine Adverse Event Reporting System and v-safe","volume":"22","author":"Rosenblum","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1007\/s00414-021-02706-9","article-title":"Postmortem investigation of fatalities following vaccination with COVID-19 vaccines","volume":"135","author":"Schneider","year":"2021","journal-title":"Int. J. Leg. Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1002\/ana.26172","article-title":"COVID-19 vaccine-associated cerebral venous thrombosis in Germany","volume":"90","author":"Schulz","year":"2021","journal-title":"Ann. Neurol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"5876","DOI":"10.3390\/jcm10245876","article-title":"Autopsy findings and causality relationship between death and COVID-19 vaccination: a systematic review","volume":"10","author":"Sessa","year":"2021","journal-title":"J. Clin. Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"3636","DOI":"10.1111\/jocd.15261","article-title":"Cutaneous adverse reactions following COVID-19 vaccinations: a systematic review and meta-analysis","volume":"21","author":"Shafie","year":"2022","journal-title":"J. Cosmet. Dermatol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"117607","DOI":"10.1016\/j.jns.2021.117607","article-title":"Vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis post COVID-19 vaccination; a systematic review","volume":"428","author":"Sharifian-Dorche","year":"2021","journal-title":"J. Neurol. Sci."},{"key":"B34","doi-asserted-by":"publisher","first-page":"80","DOI":"10.13885\/j.issn.1000-2812.2023.02.01","article-title":"Efficacy and safety of a novel coronavirus infection vaccine in cancer patients","volume":"49","author":"Shuangming","year":"2023","journal-title":"J LanZhou Univ. Med. Sci."},{"key":"B35","doi-asserted-by":"publisher","first-page":"467","DOI":"10.3390\/ijerph20010467","article-title":"COVID-19 vaccination and late-onset myasthenia gravis: a new case report and review of the literature","volume":"20","author":"Virgilio","year":"2022","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"B36","doi-asserted-by":"publisher","first-page":"313","DOI":"10.3390\/vaccines10020313","article-title":"Adverse events reporting quality of randomized controlled trials of COVID-19 vaccine using the consort criteria for reporting harms: a systematic review","volume":"10","author":"Yuniar","year":"2022","journal-title":"Vaccines (Basel)"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1308768\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T07:56:34Z","timestamp":1718178994000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1308768\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,12]]},"references-count":36,"alternative-id":["10.3389\/fphar.2024.1308768"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1308768","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,12]]},"article-number":"1308768"}}